Micrus Endovascular gets approval to sell neurovascular stent in Europe

By E. Janene Geiss

Philadelphia, March 8 - Micrus Endovascular Corp. announced Wednesday that it has received the CE Mark, which allows it to begin marketing the Pharos stent for the treatment of ischemic and hemorrhagic stroke.

Micrus expects to immediately begin selling the Pharos stent in the European Union and all countries recognizing the CE Mark through its direct sales and distribution network, according to a company news release.

The Pharos stent was developed and will be brought to market under an agreement between Micrus Endovascular and Biotronik AG announced in January.

"In keeping with our strategic plan, the introduction of the Pharos stent expands our product portfolio, allowing us to compete for a greater portion of the per-procedure revenue dollar," John Kilcoyne, Micrus president and chief executive officer, said in the release.

Biotronik is a member of the Biotronik group, a Berlin, Germany, manufacturer of medical technology with a worldwide market presence. The company offers a complete line of products for diagnosis, treatment and advanced therapy support in the areas of cardiac rhythm management, electrophysiology and vascular intervention. The vascular intervention portfolio comprises of guide wires, balloon catheters and stent systems for coronary and peripheral applications.

San Jose, Calif.-based Micrus develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.